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Activity of the multikinase inhibitor dasatinib against ovarian
cancer cells
GE Konecny*,1,2, R Glas1, J Dering1, K Manivong1, J Qi1, RS Finn1, GR Yang1, K-L Hong1, C Ginther1,
B Winterhoff2, G Gao3, J Brugge3 and DJ Slamon1
1Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles,
CA, USA; 2Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA; 3Department of Cell Biology,
Harvard Medical School, Boston, MA, USA
BACKGROUND: Here, we explore the therapeutic potential of dasatinib, a small-molecule inhibitor that targets multiple cytosolic and
membrane-bound tyrosine kinases, including members of the Src kinase family, EphA2, and focal adhesion kinase for the treatment of
ovarian cancer.
METHODS: We examined the effects of dasatinib on proliferation, invasion, apoptosis, cell-cycle arrest, and kinase activity using a panel of
34 established human ovarian cancer cell lines. Molecular markers for response prediction were studied using gene expression profiling.
Multiple drug effect/combination index (CI) isobologram analysis was used to study the interactions with chemotherapeutic drugs.
RESULTS: Concentration-dependent anti-proliferative effects of dasatinib were seen in all ovarian cancer cell lines tested, but varied
significantly between individual cell lines with up to a 3 log-fold difference in the IC50 values (IC50 range: 0.001–11.3mmol l
1).
Dasatinib significantly inhibited invasion, and induced cell apoptosis, but less cell-cycle arrest. At a wide range of clinically achievable
drug concentrations, additive and synergistic interactions were observed for dasatinib plus carboplatin (mean CI values, range:
0.73–1.11) or paclitaxel (mean CI values, range: 0.76–1.05). In this study, 24 out of 34 (71%) representative ovarian cancer cell lines
were highly sensitive to dasatinib, compared with only 8 out of 39 (21%) representative breast cancer cell lines previously reported.
Cell lines with high expression of Yes, Lyn, Eph2A, caveolin-1 and 2, moesin, annexin-1, and uPA were particularly sensitive to
dasatinib.
CONCLUSIONS: These data provide a clear biological rationale to test dasatinib as a single agent or in combination with chemotherapy
in patients with ovarian cancer.
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Ovarian cancer is a leading cause of cancer death among women
in the United States and Western Europe and has the highest
mortality rate of all gynaecologic cancers. Despite the fact that
maximal cytoreductive surgery followed by combination chemo-
therapy increases 5-year survival rates, the overall survival gains
have been modest with low overall cure rates (Aletti et al, 2007).
Thus, novel systemic treatment approaches are urgently needed.
Src is the prototypic member of a family of nine non-receptor
tyrosine kinases (Src, Lyn, Fyn, Lck, Hck, Fgr, Blk, Yrk, and Yes)
that has a key role in many cellular signalling pathways (reviewed
in Thomas and Brugge, 1997). Src family kinase (SFK) proteins
regulate four main cellular functions that ultimately control the
behaviour of transformed cells: cell proliferation, adhesion,
invasion, and motility (Summy and Gallick, 2003; Yeatman,
2004). Interactions with activated EGFR (Tice et al, 1999), HER2
(Muthuswamy et al, 1994), fibroblast growth factor receptor
(Landgren et al, 1995), or hepatocyte growth factor (Mao et al,
1997) can result in Src activation, most likely by disrupting the
intramolecular interactions that hold Src in a closed and inactive
configuration (Thomas and Brugge, 1997). Importantly, aberrant
expression and activation of the SFKs have been described in
human ovarian cancer cell lines (Budde et al, 1994) and clinical
samples (Wiener et al, 2003). A recent study used gene expression
signatures that define the status of Src signalling pathways to
predict the probability of Src pathway activation in 119 patients
with ovarian cancer (Dressman et al, 2007). Approximately half of
the tumours examined in this study showed Src pathway
deregulation. Furthermore, those patients with a deregulated Src
pathway also showed the worst prognosis.
Dasatinib is a small molecule that inhibits not only recombinant
kinase domains of SFKs such as Src, Lck, and Yes, but also other
tyrosine kinases such as Abl, c-Kit, and platelet-derived growth
factor receptor-b (PDGFR-b) by 50% (IC50) at low nanomolar
concentrations (Lombardo et al, 2004). Moreover, recent studies
have also identified focal adhesion kinase (FAK; Bantscheff et al,
2007) and EphA2 (Huang et al, 2007) as direct targets of dasatinib.
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Focal adhesion kinase is a non-receptor tyrosine kinase involved
in the regulation of cell adhesion, survival, and migration, which
itself can be activated by Src (Fincham and Frame, 1998; Schaller,
2001). Importantly, preclinical studies indicate that FAK has a
significant role in ovarian cancer cell migration and invasion
(Sood et al, 2004). The Eph receptor tyrosine kinases and ephrin
ligands have been studied extensively for their roles in develop-
mental processes. However, in recent years, Eph receptors and
ephrins have been found to be integral players in cancer formation
and progression (Wykosky and Debinski, 2008). Eph2A, as well as
other members of the Eph receptor tyrosine kinase family, have
been associated with advanced ovarian cancer and poor clinical
outcome (Thaker et al, 2004; Wu et al, 2006; Kumar et al, 2007;
Alam et al, 2008). On the basis of these data, we hypothesise that
dasatinib, which targets SFKs as well as FAK and Eph2A, may show
significant preclinical activity in ovarian cancer cells supporting its
further clinical evaluation. Thus far, dasatinib has proven to be
clinically active in patients with imatinib-refractory chronic
myelogenous leukaemia and Philadelphia chromosome-positive
ALL (Talpaz et al, 2006). Moreover, dasatinib has also recently
shown preclinical activity in prostate cancer cells (Nam et al,
2005), basal-like breast cancer cells (Finn et al, 2007), melanoma
cells (Eustace et al, 2008), colon cancer cells (Serrels et al,
2006), and head and neck squamous cancer cells or non-small-cell
lung cancer cells (Johnson et al, 2005; Song et al, 2006). Inhibitory
effects of dasatinib on cell migration and invasion of epithelial
tumour cells have been well documented in these studies, indi-
cating that dasatinib may not only have anti-proliferative but also
anti-invasive and anti-metastatic activity in epithelial tumours.
Our primary aim was to more comprehensively explore the
growth-inhibitory effects of this multikinase inhibitor using a large
panel of ovarian cancer cell lines, representing all histological
subtypes of the disease. To more fully understand the activity,
we also studied the effects of dasatinib on cell cycle invasion
and apoptosis. Furthermore, we sought to validate previously
reported, as well as identify novel response markers, all of which
are known to be implicated in Src signalling. Finally, we used
multiple drug effect/combination index (CI) isobologram analysis
to study the efficacy of chemotherapeutic drugs plus dasatinib
combinations tested against dasatinib-sensitive ovarian cancer
cells. The current studies were intended to provide a rationale to
test dasatinib as a single agent or in combination with chemo-
therapy in patients with ovarian cancer and to identify molecular
markers that may help define subsets of ovarian cancer patients
most likely to benefit from treatment with dasatinib.
MATERIALS AND METHODS
Cell lines, cell culture, and reagents
The cell lines CAOV3, ES2, OV90, TOV112D, TOV21G, SW626, and
OVCAR3 were obtained from the American Type Culture
Collection (ATCC, Rockville, MD, USA). The cell lines A2780,
OAW28, and OAW42 were obtained from the European Collection
of Cell Cultures (Salisbury, UK). The cell lines COLO704, EFO21,
and EFO27 were obtained from the German Tissue Repository
DSMZ (Braunschweig, Germany). The cell lines MCAS, OVISE,
OVKATE, OVMANA, OVSAHA, OVTOKO, and RMG1 were
obtained from the Japanese Health Science Research Resources
Bank (Osaka, Japan). The cell lines OVCAR5, OV167, OV177,
OV207, DOV13, and HEYC2 were a kind gift from Dr V Shridhar
(Mayo Clinic, Rochester, MN, USA). The cell line PE06 was a kind
gift from Dr SP Langdon (Edinburgh Cancer Research Center,
University of Edinburgh, Edinburgh, UK). The cell line HEY was a
kind gift from Dr DT Curiel (University of Alabama at
Birmingham, Birmingham, AL, USA). The cell lines SKOV3,
OV2008, OVCA420, OVCA429, OVCA432, and OVCA433 were a
kind gift from Dr B Karlan (Cedars Sinai, Los Angeles, CA, USA).
The individuality of each cell line was checked by mitochondrial
DNA sequencing. OV167, OV177, and OV207 cells were cultured in
MEM medium (Fisher Scientific, Pittsburgh, PA, USA) plus 20%
fetal bovine serum (FBS). OVCA420 and OVCA429 cells were
cultured in MEM medium (Fisher Scientific) plus 10% FBS. EFO27
and EFO21 cells were cultured in RPMI 1640 medium (ATCC) plus
20% FBS and 1% MEM Non-Essential Amino Acid Solution
(ATCC). COLO704, HEY, OV2008, OVISE, OVMANA, OVTOKO,
OVKATE, and OVSAHO cells were cultured in RPMI 1640 medium
plus 10% FBS. MCAS, DOV13, OVCA432, and OVCA433 cells were
cultured in Eagle’s minimal essential medium (ATCC) plus 15%
FBS. RMG1 cells were cultured in Ham’s F12 (ATCC) plus 10%
FBS. SW626 cells were cultured in Leibovitz’s L-15 medium
(ATCC) plus 10% FBS. HEYC2 and PE06 cells were cultured in
DMEM/F12 (ATCC) plus 10% FBS. OAW42 and OAW28 cells were
cultured in DMEM (ATCC) plus 10%FBS. ES2 and SKOV3 were
cultured in McCoy’s 5A medium (ATCC) plus 10% FBS. OVCAR5,
OVCAR3, and CAOV3 cells were cultured in DMEM medium plus
10% FBS and 4.5 g l1 glucose. A2780 cells were cultured in RPMI
1640 medium plus 10% FBS and 0.25Uml1 insulin. OV90,
TOV21G, and TOV112D cells were cultured in a 1 : 1 mixture of
MCDB 105 medium (Cell Applications Inc., San Diego, CA, USA)
and Medium 199 (Sigma-Aldrich, St Louis, MO, USA) plus 15%
FBS. All cell line cultures were supplemented with 1% penicillin–
streptomycin and 1% L-glutamine. Dasatinib was provided by
Bristol-Myers Squibb (New York, NY, USA) and prepared as a
10mmol l1 concentrated stock solution in DMSO.
Proliferation assays
Cells were plated into 24-well tissue culture plates at a density of
2 105 to 5 105 and grown in cell-line-specific medium without
or with increasing concentrations of dasatinib (ranging between
0.001 and 10 mmol l1). Cells were counted on day 7 using an
automated cell viability assay (Vi-CELL XR Cell Viability Analyzer,
Beckman Coulter, Fullerton, CA, USA), which is a video imaging
system using an automated trypan blue exclusion protocol. Both
adherent and floating viable cells were counted for treatment and
control wells. Growth inhibition (GI) was calculated as a
percentage of untreated controls. The log of the fractional GI
was then plotted against the log of the drug concentration and the
IC50 values were interpolated from the resulting linear regression
curve fit (CalcuSyn; Biosoft, Ferguson, MO, USA). Experiments
were performed thrice in duplicate for each cell line.
Cell cycle analysis
Cells were plated in six-well tissue culture plates and treated with
vehicle (0.1% DMSO) or 1 mmol l1 dasatinib for 72 h. After
collection, the cells were fixed in 70% ethanol, incubated in HCl/
Triton X-100, and stained with propidium iodide. Samples were
analysed by flow cytometry (Becton Dickinson, San Jose, CA, USA)
according to the manufacturer’s protocol.
Annexin V and propidium iodide flow cytometry
Cells were treated with 1 mmol l1 dasatinib for 5 days. Apoptotic
subpopulations were detected by labelling phosphatidylserine
residues of the cell surface with annexin V-FITC and staining
cells with propidium iodide. Detection was carried out on floating
and adherent cell fractions by two-colour flow cytometry (Becton
Dickinson) according to the manufacturer’s protocol.
Invasion assay
Invasion assays were carried out as previously described (Glynn
et al, 2004). Briefly, Matrigel (BD Biosciences, San Jose, CA, USA)
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was diluted to 1mgml1 in serum-free medium. A volume of
100ml of Matrigel was placed into each insert (Falcon) (8.0mm
pore size), which stood in wells of a 24-well plate (Costar, Lowell,
MA, USA). The inserts and the plate were incubated for 5 h at
371C for gelling. Cells were then suspended in serum-free culture
media at a concentration of 106ml1. Subsequently, 100ml of
the cell suspension was added to each insert and 500ml culture
media containing 10% FBS was added to the bottom well. Cells
were incubated at 371C in culture media with or without 1 mmol l1
dasatinib for 48 h. After this time period, the top side of the insert
was wiped with a wet swab to remove the cells and the insert was
stained with 0.25% crystal violet. Cells entering the Matrigel layer
were viewed at  200 magnification and counted in four random
fields per sample. All assays were carried out in triplicate.
Western blot and immunoprecipitation
Cells were washed in PBS and lysed at 41C in lysis buffer. Insoluble
material was cleared by centrifugation at 10 000 g for 10min.
Protein was quantitated using BCA (Pierce, Rockford, IL, USA),
resolved by SDS–PAGE, and transferred to nitrocellulose mem-
branes (Invitrogen Life Technologies, Carlsbad, CA, USA).
Phosphorylated Src was detected by an anti-pSrc antibody
(Tyr416, Calbiochem, San Diego, CA, USA). Phosphorylated FAK
was detected using an anti-pFAK antibody (Tyr576/577, Invitrogen
Life Technologies). Tyrosine phosphorylation of Yes, Lyn, and
Eph2A was analysed as follows. Immunoprecipitations were
performed by allowing 250 mg protein lysate to incubate with
3 mg anti-Yes (C-10, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), anti-Lyn (H-70, Santa Cruz Biotechnology), and anti-EphA2
antibodies (L-20, Santa Cruz Biotechnology) and protein
A/G-agarose (Santa Cruz Biotechnology) at 41C overnight with
gentle agitation. The immunoprecipitates were washed thrice in
lysis buffer and then denatured in Laemmli buffer before SDS–
PAGE. Immunoblotting was performed using a monoclonal anti-
phosphotyrosine antibody (Y20, Becton Dickinson Biosciences,
San Jose, CA, USA). Detection was carried out using enhanced
chemiluminescence (ECL; Amersham Biosciences UK, Buckin-
ghamshire, England).
Multiple drug effect analysis
Aliquots of 3 103 to 5 103 OVCAR3, OVCAR5, RMG1, and
SKOV3 cells were plated in 96-well microdilution plates. After cell
adherence (24 h), experimental medium containing control med-
ium, dasatinib, carboplatin or paclitaxel, or the combination
(dasatinib plus carboplatin or paclitaxel) was added to appropriate
wells in duplicate, and serial twofold dilutions were performed to
span clinically relevant concentration ranges for the dose-effect
analysis for dasatinib and chemotherapeutic agent or drug combi-
nation. Multiple drug effect analysis was carried out as previou-
sly described (Pegram et al, 2004). Combination index values were
derived from variables of the median effect plots and statistical
tests were applied (unpaired, two-tailed Student’s t-test) to deter-
mine whether the mean CI values at multiple effect levels were
significantly different from CI¼ 1. In this analysis, synergy is
defined as CI values significantly lower than 1.0, antagonism as CI
values significantly higher than 1.0, and additivity as CI values
equal to 1.0.
Gene expression profiling of ovarian cell lines
Agilent microarray analyses were developed for each cell line.
Briefly, cells were grown to log phase and then RNA was extracted
using the RNeasy Kit (Qiagen, Valencia, CA, USA). The purified
RNA was eluted in 30–60 ll DEPC water and the quantity of RNA
measured by spectral analysis using the Nanodrop Spectro-
photometer. RNA quality was determined by separation of the
OV2008 SKOV3OV207
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Figure 1 The influence of dasatinib treatment on the detachment of
viable cells grown in culture was studied by comparing the fraction of
floating cells between dasatinib-treated and control cells. Cells were treated
with 0.5mmol l1 dasatinib. Cells were counted on day 3 by an automated
cell viability assay using an automated trypan blue exclusion protocol. Both
adherent and floating viable cells were counted for treatment and control
wells. Our results indicate that dasatinib can slightly increase the fraction of
floating viable cells grown in culture. Therefore, both adherent and floating
viable cells were analysed in the cell count experiments used for assessing
growth inhibition.
Table 1 Dasatinib concentrations that achieve IC50 and percent growth
inhibition compared with untreated controls at a fixed concentration of
1mmol l1 dasatinib
Cell line
IC50
(lmol) s.e.
Growth inhibition
in % at 1 lmol s.e. Histology
HEY 0.001 0.001 95 1.1 Serous
SKOV3 0.005 0.004 82 1.3 Serous
OVCAR3 0.007 0.001 75 8.0 Serous
EFO27 0.019 0.009 84 4.1 Mucinous
OVCAR5 0.023 0.018 71 4.9 Undifferentiated
OVTOKO 0.030 0.022 81 5.8 Clear cell
OVMANA 0.046 0.023 66 7.7 Clear cell
OVSAHO 0.056 0.014 69 10.1 Serous
OVISE 0.062 0.017 73 3.8 Clear cell
OV177 0.072 0.051 67 6.7 Serous papillary
OV207 0.080 0.038 69 1.9 Clear cell
RMG-1 0.082 0.043 71 4.6 Clear cell
CAOV3 0.084 0.038 68 4.8 Serous
TOV21G 0.094 0.036 88 0.4 Clear cell
OVCA429 0.113 0.068 68 7.0 Clear cell
DOV13 0.130 0.112 80 6.7 Serous
MCAS 0.196 0.097 67 5.3 Mucinious
OV90 0.209 0.043 78 3.1 Serous
EFO21 0.216 0.057 64 5.7 Serous
HEY-C2 0.221 0.062 55 3.5 Serous
OVCA420 0.243 0.127 78 4.6 Serous
OAW42 0.538 0.149 64 5.3 Serous
PEO6 0.562 0.416 48 5.4 Serous
SW626 0.565 0.179 58 0.4 Undifferentiated
OVCA433 0.624 0.440 70 7.0 Serous
OV2008 0.688 0.334 63 4.5 Endometrioid
OVCA432 0.906 0.530 66 7.7 Serous
OV167 1.905 0.587 52 10.3 Serous
TOV112D 2.565 0.953 34 9.1 Endometrioid
A2780 2.829 0.638 44 5.5 Undifferentiated
OAW28 3.760 0.742 43 2.1 Serous
ES-2 5.519 1.436 28 7.4 Clear cell
COLO704 6.428 1.996 29 5.6 Undifferentiated
OVKATE 11.229 1.229 25 4.7 Serous
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RNA through capillary electrophoresis using the Agilent 2000
Bioanalyzer (Agilent, Santa Clara, CA, USA). Microarray hybridi-
sations of 34 ovarian cell lines were performed using the Agilent
Human 1A V2 array. Characterisation of individual ovarian cancer
cell lines by comparison with an ovarian cancer cell line mixed
reference pool was conducted on a single slide in which the mixed
pool RNA was labelled with cyanine-3 and the individual cell lines
with cyanine-5. The mixed reference pool consisted of equal
amounts of cRNA from all ovarian cancer cell lines examined.
Microarray slides were read using an Agilent Scanner and the
Agilent Feature Extraction software version 7.5 was used to
calculate gene expression values. The feature-extracted files were
imported into the Rosetta Resolver system for gene expression
data analysis (version 7.2; Rosetta Biosoftware, Seattle, WA, USA).
The intensity ratios between the cell line sample and mixed
reference were calculated for each sequence and computed accor-
ding to the Agilent error model. A particular sequence was consi-
dered differentially expressed if the calculated P-value was p0.01.
Statistical methods
The Resolver System ratio-splitting operation was used to generate
intensity profiles from the set of ovarian cell line ratio scans and
breast cell line ratio scans previously described (Finn et al, 2007).
The ratio-splitting operation includes error modelling of the
channels of each ratio scan, group normalisation, forward
transformation of intensities, group detrending, inter-slide error
correction, and finally inverse transformation of intensities. After
ratio splitting, the ovarian cell lines and breast cell lines were
clustered across a set of genes related to dasatinib sensitivity.
The two-dimensional cluster analysis was carried out using an
agglomerative hierarchical clustering algorithm based on the
cosine correlation similarity metric. Before clustering, the intensity
values were converted to Z-scores using the Resolver System data
processing pipeline. The Z-score transformation converts the mean
for each gene to zero and the standard deviation is set to 1. The
cluster data were exported, and associations between the expres-
sion levels of biomarkers (Z-scores) and GI were analysed using
Spearman’s r-correlation, and differences between the subgroups
were compared using Student’s t-test. Cells with X60% GI were
classified as highly sensitive, cells with 40–59% GI as moderately
sensitive, and cells with o40% GI as resistant. All statistical tests
were two-sided.
RESULTS
Activity of dasatinib in ovarian cancer cells
The effects of dasatinib on human ovarian cancer cells were
evaluated using a panel of 34 established human ovarian cancer
cell lines. These cells lines were selected to be representative of a
range of ovarian cancer subtypes. Of these cell lines, 18 cell lines
were obtained from patients with serous papillary ovarian cancer,
8 cell lines from patients with clear cell ovarian cancer, and 4 cell
lines from patients with undifferentiated ovarian cancer.
The remaining four cell lines were obtained from patients with
endometrioid or mucinous ovarian cancer. Earlier reports indicate
that dasatinib may inhibit cell-surface adhesion of epithelial
tumour cells grown in culture (Nam et al, 2005; Serrels et al, 2006).
To study the influence of dasatinib treatment on the detachment of
viable cells grown in culture, we compared the fraction of floating
cells between dasatinib-treated and control cells. Our results
indicate that dasatinib can slightly increase the fraction of floating
viable cells grown in culture (Figure 1). Therefore, both adherent
and floating viable cells were analysed in the cell count experi-
ments used for assessing GI. The effective dose range (IC10–IC80)
was identified using a wide range of dasatinib concentrations
(0.001–10 mmol l1). Dasatinib inhibited the proliferation of all
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Figure 2 Growth inhibitory effects of dasatinib were studied across a panel of ovarian cancer cell lines. Cells were grown in cell line-specific media without
or with increasing doses of dasatinib (ranging between 0.001 and 10mmol l1). Cells were trypsinised and counted after 7 days of treatment. The percentage
of inhibition was calculated compared with untreated controls. The log of the fractional growth inhibition (GI) was plotted against the log of the drug
concentration. The dose achieving 50% GI (IC50) was interpolated from the resulting linear regression curve fit. Cell lines are ordered from left to right from
low to high IC50 values. Error bars indicate the s.e. of the mean value. Mean is derived from three replicate experiments.
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ovarian cancer cell lines investigated in a concentration-dependent
manner; however, the IC50 values varied significantly between
individual cell lines with up to a 3 log-fold difference in the IC50
values and ranged between 0.001 mmol l1 in HEY ovarian cancer
cells and 11.3 mmol l1 in OVKATE ovarian cancer cells (Table 1
and Figure 2). When comparing the sensitivity with dasatinib
between histological subtypes, none of the serous papillary, clear
cells, or the endometrioid, mucinous, or undifferentiated ovarian
cancer cells were preferentially sensitive to dasatinib (data not
shown). We have previously reported on the growth inhibitory
effect of dasatinib in a large representative panel of 39 breast
cancer cell lines (Finn et al, 2007). When treated with dasatinib
in vitro, 8 (21%) of them were highly sensitive (X60% GI), 10 of
them were moderately sensitive (40–59% GI), and 21 were resistant
(o40% GI) to dasatinib. The results of this study indicate that 24
out of the 34 (71%) ovarian cancer cell lines were highly sensitive
(X60% GI), 6 of them were moderately sensitive (40–59% GI),
and only 4 were resistant to dasatinib (o40% GI). Importantly,
we used the identical cell proliferation assays for assessing GI in
both the breast and the ovarian cancer cell line panels.
Predictors of dasatinib response in vitro
A key aspect of therapies with targeted agents is the accurate
selection of patients most likely to benefit from therapy. Earlier
reports have shown that high expression of annexin-1, caveolin-1,
caveolin-2, moesin, and uPA, as well as low expression of IGFBP2,
was associated with the in vitro response to dasatinib in breast,
lung, and prostate cancer cells (Finn et al, 2007; Huang et al, 2007;
Wang et al, 2007). Here, we explored the association between the
various biomarkers implicated in Src signalling pathways and the
in vitro response to dasatinib in 73 human cancer cell lines,
including the current 34 ovarian cancer cell lines and 39 breast
cancer cell lines that have been published earlier (Finn et al, 2007).
Restricting such a correlative analysis between the in vitro
response and differential gene expression to only ovarian cancer
cell lines would be of limited value as most ovarian cancer cell lines
were highly sensitive and only four ovarian cancer cell lines
showed resistance (defined as o40% GI) and only seven ovarian
cancer cell lines showed an IC50 41 mM. Importantly, in vitro
sensitivity towards dasatinib was assessed using the same
methodology in the ovarian and breast cancer cell line panels,
and cell lines were uniformly classified as highly sensitive (X60%
GI), moderately sensitive (40–59% GI), and resistant to dasatinib
(o40% GI). Of the known dasatinib targets, high expression of
Yes, Lyn, and EphA2 but not of Src, FAK, Kit, or PDGFR-b was
associated with in vitro sensitivity to dasatinib (Figure 3, Table 2).
Furthermore, our findings corroborate earlier data, in that cell
lines with high expression of annexin-1, caveolin-1, caveolin-2,
moesin, and uPA but low expression of IGFBP2 were the most
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Figure 3 Microarray hybridisations of 34 ovarian cell lines were performed using the Agilent Human 1A V2 array. Characterisation of individual ovarian
cancer cell lines by comparison with an ovarian cancer cell line mixed reference pool was conducted on a single slide in which the mixed pool RNA was
labelled with cyanine-3 and the individual cell lines with cyanine-5. The mixed reference pool consisted of equal amounts of cRNA from all ovarian cancer
cell lines examined. The Resolver System was used to generate intensity profiles from the set of ovarian cell line ratio scans and breast cell line ratio scans
previously described (Finn et al, 2007). The red and green matrices represent the normalised expression patterns for each gene in Table 2 across the
34 ovarian and 39 breast cancer cell lines. Brightest red indicates the highest relative expression and brightest green indicates the lowest relative expression.
The bottom 2 rows are matrices that represent the in vitro sensitivity to dasatinib (blue¼ highly sensitive, X60% growth inhibition (GI); red¼moderately
sensitive, 40–59% GI; and green¼ resistant, o40% GI), and the cell line origin (yellow¼ ovarian cancer cell line; blue¼ breast cancer cell line).
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sensitive to dasatinib (Figure 3, Table 2). We also studied addi-
tional markers such as E-cadherin, P-cadherin, and N-cadherin
that have an important role in cell adhesion, as well as b-catenin
and d-catenin/p120, both found in complexes with cadherin
molecules. Our results indicate that cell lines with high expression
of E-cadherin or P-cadherin, as well as d-catenin/p120, were less
sensitive to dasatinib when compared with those with lower
expression of the respective markers (Figure 3, Table 2). We also
studied the expression of receptor tyrosine kinases such as HER2
and MET or components of the VEGF/STAT3 signalling pathway,
which can all signal through Src (Mukhopadhyay et al, 1995;
Rahimi et al, 1998; Laird et al, 2003; Vadlamudi et al, 2003).
Surprisingly, high expression of HER2, MET, or VEGF and STAT3
was not associated with in vitro sensitivity to dasatinib; in fact,
high expression of HER2, VEGF, and STAT3 was rather correlated
with in vitro resistance to dasatinib.
Effects of dasatinib on ovarian cancer cell cycling,
survival, and invasion
Earlier reports have suggested that dasatinib may have anti-
proliferative activity by inducing cell cycle arrest and apoptosis
in lung or head and neck cancer cells (Johnson et al, 2005; Song
et al, 2006), malignant pleura mesothelioma (Tsao et al, 2007),
or melanoma cells (Eustace et al, 2008). Here, we confirm and
extend these findings to ovarian cancer cells. At a concentration of
1 mmol l1, dasatinib treatment significantly increased the fraction
of early and late apoptotic cells in the human ovarian cancer cell
lines examined (Figure 4). In contrast, however, treatment with
1 mmol l1 dasatinib over 72 h only lead to a modest increase in the
fraction of cells in the G0/G1 cell cycle phase in only one out of the
four examined human ovarian cancer cell lines when compared with
the untreated controls (Figure 5). At a concentration of 1mmol l1,
dasatinib treatment also significantly inhibited the ability of ovarian
cancer cells to invade matrigel when compared with untreated
controls in all of the four examined cell lines (Figure 6).
Effects of dasatinib on Src, Yes, Lyn, FAK, and Eph2A
phosphorylation
We assessed the effect of dasatinib on the phosphorylation state
of Src, Lyn, Yes, EphA2, and FAK using immunoblotting tech-
niques. Exposure of EFO27, CAOV3, OVKATE, OVCAR3, A2780,
COLO704, OV167, and OVCAR5 cells to 1 mmol l1 dasatinib for
1 h resulted in a pronounced reduction of pSrc, pYes, pLyn,
pEphA2, and pFAK (Figure 7).
Combination of dasatinib and chemotherapeutic agents
We next analysed the combination of dasatinib and chemother-
apeutic agents used for the treatment of ovarian cancer. Multiple
Table 2 Association between in vitro growth inhibition after dasatinib treatment (at a concentration of 1mmol l1) and the relative expression of
biomarkers implicated in Src signaling pathways in 34 ovarian and 39 breast cancer cell lines (Finn et al, 2007)
Name Symbol Correlation coefficienta P-value
Urokinase plasminogen activator UPA 0.63 o0.001
Moesin MSN 0.60 o0.001
Caveolin-2 CAV2 0.57 o0.001
Caveolin-1 CAV1 0.54 o0.001
Ephrin A2 Eph2A 0.53 o0.001
Annexin-1 ANAX1 0.53 o0.001
Yamaguchi sarcoma viral related oncogene homolog LYN 0.41 0.016
Yamaguchi sarcoma viral oncogene homolog 1 YES 0.36 0.002
Hepatocyte growth factor receptor MET 0.19 0.111
N-cadherin CDH2 0.19 0.105
Beta-catenin CTNNB1 0.10 0.390
v-src sarcoma viral oncogene homolog SRC 0.23 0.046
Signal transducer and activator of transcription-3 STAT3 0.26 0.029
c-abl ABL 0.27 0.021
P-cadherin CDH3 0.34 0.003
Focal Adhesion Kinase PTK2 0.35 0.003
E-cadherin CDH1 0.38 0.001
c-kit KIT 0.41 o0.001
Human epidermal growth factor receptor-2 HER2 0.43 o0.001
Vascular endothelial growth factor VEGFA 0.43 o0.001
Insulin-like growth factor binding protein-2 IGFBP2 0.47 o0.001
Platelet derived growth factor receptor-b PDGFRB 0.55 o0.001
Delta-catenin/p120 CTNND1 0.55 o0.001
Cell lines were classified as highly sensitive (X60% growth inhibition, moderately sensitive (40–59% growth inhibition), and resistant (o40% growth inhibition). aSpearman’s
r-correlation.
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Figure 4 Detection of apoptotic subpopulations was achieved by
labelling phosphatidylserine residues of the cell surface with annexin V-FITC
and staining cells with propidium iodide. Cells were treated with 1mmol l1
dasatinib for 5 days. This staining allows differentiation between early (Q4)
and late (Q2) apoptotic subpopulations.
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drug effect analysis was performed using four dasatinib-sensitive
ovarian cancer cell lines to determine the nature of the interaction
between dasatinib and carboplatin or paclitaxel (synergy, addition,
or antagonism). The dasatinib concentrations used for these experi-
ments ranged between 0.031 and 0.5mmol l1 for OVCAR5, 0.050
and 0.8mmol l1 for SKOV3 cells, 0.008 and 0.125mmol l1 for RMG1,
and 0.016 and 0.250mmol l1 for CAOV3 cells and were below the
reported peak plasma concentrations achievable in humans (Wang
et al, 2008). The drug concentrations of carboplatin and paclitaxel
used for these experiments were similarly below the reported
peak plasma concentrations that have been previously published
(Pegram et al, 2004). Synergistic and additive interactions
were observed for dasatinib plus carboplatin (mean CI values
ranged from 0.73 (95% CI: 0.56–0.90, P¼ 0.002) in RMG1 cells to
1.11 (95% CI: 0.77–1.46, P¼ 0.553) in OVCAR5 cells) and for
dasatinib plus paclitaxel (0.76 (95% CI: 0.54–0.99, P¼ 0.016) in
SKOV3 cells to 1.05 (95% CI: 0.87–1.23, P¼ 0.524) in OVCAR5
cells) (Figure 8).
DISCUSSION
Although the Src kinase has been linked with the development and
progression of cancer for many years, there has only recently been
a renewed interest in this onco-protein as a molecular target for
cancer therapy. Src family kinases modulate signal transduction
through multiple oncogenic pathways, including EGFR, HER2,
PDGFR, FGFR, and VEGFR (Yeatman, 2004). In turn, a wide range
of Src substrates have been identified that regulate cell growth,
adhesion, invasion, and motility (Thomas and Brugge, 1997;
Yeatman, 2004). Thus, it is anticipated that blocking Src kinase
would be predicted to have a broad therapeutic benefit in patients
with Src-dependent cancers. Dasatinib is currently being tested or
entering clinical trials in various epithelial malignancies (http://
ClinicalTrials.gov). However, despite the ubiquitous expression of
SFKs, they may have varying roles in different epithelial cancers
and, moreover, may be more important in specific disease
subgroups compared with others. Here, we are able to show that
approximately two-thirds of the ovarian cancer cell lines examined
showed high in vitro sensitivity to dasatinib, which is in stark
contrast to the fact that similar sensitivity was only seen in one-
fifth of the breast cancer cell lines examined. Nevertheless, we still
found a wide range of in vitro response to dasatinib with up to a
threefold log difference in IC50 values between the most sensitive
and the most resistant cell lines. We therefore sought to validate
biomarkers that predict in vitro response to dasatinib. In doing so,
we focused primarily on biomarkers that have been reported
earlier or that are known to be implicated in Src signalling. We
intended to identify a limited number of individual response
markers that may be more useful for independent validation in
future clinical studies. Our results confirm data from earlier
studies that were obtained in breast, lung, and prostate cancer cell
lines, in that high expression levels of caveolin-1, caveolin-2,
annexin-1, moesin, Eph2A, and uPA were associated with in vitro
sensitivity to dasatinib (Finn et al, 2007; Huang et al, 2007; Wang
et al, 2007). Caveolins are membrane proteins involved in
receptor-independent endocytosis and can be upregulated during
epithelial-to-mesenchymal transition (Bailey and Liu, 2008).
Moesin, a member of the ezrin/radixin/moesin family of actin-
binding proteins, cross-links the actin cytoskeleton to the plasma
membrane (Rosenblatt, 2008) and recent data suggest that cell
movement through rapid actin cytoskeleton remodelling is
mediated by moesin activation (Fu et al, 2008). Thus, high
expression of these two markers that are involved in cell adhesion
and migration may characterise a cell phenotype that is
particularly susceptible to Src inhibition. Moreover, of the known
dasatinib targets, increased expression of Eph2A, Yes, and Lyn was
associated with in vitro sensitivity to dasatinib.
Normal epithelial architecture and function are maintained by
integrins and cadherins, transmembrane receptors that mediate
cell–ECM and cell–cell interactions, respectively. Importantly,
signalling centres organised by these receptors modulate ancho-
rage dependence and contact-dependent inhibition of cell growth,
which are essential cellular functions often disrupted in cancer.
E-cadherin is the main cell–cell adhesion molecule in epithelial
tissues and is regarded as a master organiser of the epithelial
phenotype. E-cadherin is regulated in part by cytoplasmic binding
partners called catenins (b-catenin, and p120-catenin). b-Catenins
are primarily associated with physical and/or functional linkage to
the actin infrastructure (Yamada et al, 2005), whereas p120-catenin
appears to modulate cadherin stability at the cell surface (Ireton
et al, 2002; Reynolds and Roczniak-Ferguson, 2004). Thus, high
expression of E-cadherin and p120-catenin, which are hallmarks of
an epithelial cell phenotype, may characterise tumour cells that are
less susceptible to Src inhibition.
Our study also confirms that low expression of IGFBP2 may be
associated with in vitro sensitivity to dasatinib (Huang et al, 2007).
Conversely, high expression of IGFBP2 may thus characterise a cell
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Figure 5 Cell cycle analysis of cells treated with dasatinib. Cells were
treated with vehicle (0.1% DMSO) or 1 mmol l1 dasatinib for 72 h. Cells
were analysed by flow cytometry after propidium iodide staining.
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Figure 6 Invasion was assessed using Matrigel invasion assays as
described in Materials and methods. Cells were incubated at 371C in
culture media with or without 1 mmol l1 dasatinib for 48 h. Cells invading
the Matrigel layer were viewed at  200 magnification and counted in four
random fields per sample. All assays were performed in triplicate.
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phenotype less responsive to the inhibition of Src- or FAK-driven
transformation. Recent data support this hypothesis, in that
IGFBP2 was shown to independently promote cell mobility
through its interaction with integrins (Schu¨tt et al, 2004; Wang
et al, 2006). Moreover, IGFBP2 has been described to be a
candidate biomarker for PTEN status and PI3K/Akt pathway
activation (Mehrian-Shai et al, 2007).
Dasatinib was approved for the treatment of imatinib-resistant/
intolerant patients with CML or Philadelphia chromosome-
positive acute lymphoblastic leukaemia at the dosage of 70mg
twice daily. However, toxicity issues have hampered the clinical
development of this compound in epithelial malignancies.
Nevertheless, a phase III dose-optimisation study has recently
been carried out to compare the aforementioned regimen with
others, including dasatinib 100mg once daily, in patients with
CML (Tyler, 2009). The results of this study showed that there was
no significant difference in efficacy between these two regimens.
The safety profile was improved in the 100-mg once-daily
dasatinib arm with significantly reduced frequencies of grade
3–4 thrombocytopenia and all-grade pleural effusions.
The number of patients who had to discontinue, reduce, or
interrupt their dosage was also less among patients taking
dasatinib 100mg once daily (Tyler, 2009).
To determine how best to use dasatinib either as a single agent
or in combination with chemotherapy, we conducted a series of in
vitro studies to evaluate its inhibitory effects in combination with
carboplatin or paclitaxel. These preclinical studies have shown
significantly enhanced activity when chemotherapy is combined
with dasatinib in ovarian cancer cells. Taken together, our findings
support further clinical evaluation of dasatinib as a single agent or
in combination with chemotherapy in patients with ovarian
cancer. Moreover, the assessment of functionally implicated
response predictors in these clinical trials may help to identify
the patient subgroup most likely to benefit from treatment with
dasatinib.
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Figure 7 Effect of dasatinib on the phosphorylation state of Src, Lyn, Yes, EphA2, and FAK using immunoblotting techniques. Exposure of EFO27,
CAOV3, OVKATE, OVCAR3, A2780, COLO704, OV167, and OVCAR5 cells to 1 mmol l1 dasatinib for 1 h resulted in a pronounced reduction of pSrc,
pYes, pLyn, pEphA2, and pFAK.
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Figure 8 Mean CI values for chemotherapeutic drug–dasatinib
combinations in four different human ovarian cancer cell lines. Error bars
indicate the 95% confidence interval of the mean value. Mean is derived
from three replicates spanning clinically relevant concentration ranges
sufficient to inhibit growth of control cells by 20–90%. Combination index
values were derived from parameters of the median effect plots, and
statistical tests were used to determine whether the CI values at multiple
effect levels (IC20– IC90) were statistically significantly different from CI
values equal to 1. Values that are statistically significantly o1 indicate
synergistic interactions. Values that are statistically significantly 41 indicate
antagonistic interactions. Values equal to (or not statistically significantly
different from) 1 indicate additive interactions.
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